Cited by 50Liver Disease Diagnosis and TreatmentDiet, Metabolism, and DiseaseLiver physiology and pathology

SARM1 deletion restrains NAFLD induced by high fat diet (HFD) through reducing inflammation, oxidative stress and lipid accumulation

Pan, Zhen-Guo, An, Xu-Sheng·2018·Biochemical and Biophysical Research Communications

Abstract

SARM1 (Sterile alpha and armadillo motif-containing protein 1) is the recently identified TIR domain-containing cytosolic protein, which is involved in toll-like receptors (TLRs) signaling transduction. In the present study, the role of SARM1 in high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) progression was explored. We found that SARM1 was expressed highly in fatty liver. And SARM1-knockout (KO) reduced steatohepatitis and metabolic disorders induced by HFD. SARM1-deletion decreased aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in HFD-fed mice. Additionally, inflammatory response caused by HFD was alleviated by SARM1-deletion through inactivating TLR4/7/9 and nuclear factor kappa B (NF-κB) pathways. Of note, SARM1-deletion also reduced the expressions of inflammation-associated molecules in hypothalamus of HFD-fed mice. Furthermore, HFD administration led to oxidative stress in liver of mice, while being decreased in SARM1-KO mice. Moreover, SARM1-ablation improved lipid dyslipidemia by suppressing the mRNA levels of genes, linked to glycolysis, lipogenesis and transcriptional regulation. Insulin resistance was also attenuated by SARM1-deficiency through enhancing the activation of liver Akt/glycogen synthase kinase-3β (GSK3β) and insulin receptor substrate-1 (IRS1)/FOXO1 pathways in HFD-fed mice. Also, SARM1-knockout improved neuropeptide Y (NPY), Pro-Opiomelanocortins (POMC), Agouti-related Protein (AGRP) and Cocaine-and-Amphetamine Responsive Transcript 1 (CART1) expressions in hypothalamus of mice after HFD administration. In vitro, we found that the reduction of inflammatory response, oxidative stress and dyslipidemia induced by SARM1-knockout in primary hepatocytes after fructose stimulation was largely attributed to its suppression to TLR4/7/9. Together, the findings demonstrated that SARM1 might be an effective target for developing effective therapeutic strategies against NAFLD.

Integrity signals

Registry

Crossref · 10.1016/j.bbrc.2018.02.115

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SARM1 cleaves NAD+ into NAM, ADPR, and cADPR via its TIR domain and is expressed in brain and non-brain tissues including liver.

    “SARM1 is a newly recognized class of NADase that cleaves NAD+ into NAM, ADPR, and cADPR via its TIR domain. It is expressed in both brain and non-brain tissues, including the liver (Essuman et al., 2017; Pan and An, 2018).”

    From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Pan and An, 2018

The citation lists haven’t been fetched yet

References 32 · Cited by 50

Authors
Pan, Z.-G., & An, X.-S.
Venue
Biochemical and Biophysical Research Communications
Publisher
Elsevier BV
Published
2018-04
Volume
498
Issue
3
Pages
416-423
ISSN
0006-291X (ISSN-L)
OpenAlex
W2791099756
Cited by
50
References
32
Citations by year
2026: 5 · 2025: 7 · 2024: 7 · 2023: 2 · 2022: 7 · 2021: 6 · 2020: 5 · 2019: 9 · 2018: 1
FWCI
4.12
Type
journal article
Language
en
Open access
closed
Locations
  • Biochemical and Biophysical Research Communications (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
SARM1, non-alcoholic fatty liver disease, high-fat diet, NF-κB signaling, inflammation, oxidative stress, lipid accumulation, insulin resistance, hypothalamic neuropeptides, dyslipidemia, steatohepatitis, hepatocytes, fructose, FOXO1, IRS-1
MeSH terms
Animals, Cells, Cultured, Cytoskeletal Proteins, Inflammation, Insulin Resistance, Liver, Male, Mice, Inbred C57BL, Gene Deletion, Mice, Knockout, Oxidative Stress, Hepatocytes, Lipid Metabolism, Armadillo Domain Proteins, Diet, High-Fat, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review